Home LiteratureArticle Details
PMID: 15017610 Published · ppublish English Comparative Study Journal Article Multicenter Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Clinical and genetic characteristics of hereditary pancreatitis in Europe.

Howes N, Lerch MM, Greenhalf W, Stocken DD, Ellis I, Simon P, Truninger K, Ammann R, Cavallini G, Charnley RM, Uomo G, Delhaye M, Spicak J, Drumm B, Jansen J, Mountford R, Whitcomb DC, Neoptolemos JP, European Registry of Hereditary Pancreatitis and Pancreatic Cancer EUROPAC

Abstract

Hereditary pancreatitis is an autosomal dominant disease that is mostly caused by cationic trypsinogen (PRSS1) gene mutations. The aim was to determine phenotype-genotype correlations of families in Europe. Analysis of data obtained by the European Registry of Hereditary Pancreatitis and Pancreatic Cancer was undertaken using multilevel proportional hazards modelling. There were 112 families in 14 countries (418 affected individuals): 58 (52%) families carried the R122H, 24 (21%) the N29I, and 5 (4%) the A16V mutation, 2 had rare mutations, and 21 (19%) had no PRSS1 mutation. The median (95% confidence interval [CI]) time to first symptoms for R122H was 10 (8, 12) years of age, 14 (11, 18) years for N29I, and 14.5 (10, 21) years for mutation negative patients (P = 0.032). The cumulative risk (95% CI) at 50 years of age for exocrine failure was 37.2% (28.5%, 45.8%), 47.6% (37.1%, 58.1%) for endocrine failure, and 17.5% (12.2%, 22.7%) for pancreatic resection for pain. Time to resection was significantly reduced for females (P < 0.001) and those with the N29I mutation (P = 0.014). The cumulative risk (95% CI) of pancreatic cancer was 44.0% (8.0%, 80.0%) at 70 years from symptom onset with a standardized incidence ratio of 67% (50%, 82%). Symptoms in hereditary pancreatitis start in younger patients and endpoints take longer to be reached compared with other forms of chronic pancreatitis but the cumulative levels of exocrine and endocrine failure are much higher. There is an increasingly high risk of pancreatic cancer after the age of 50 years unrelated to the genotype.

MeSH Terms
Adult Age Distribution Age of Onset Confidence Intervals Europe/epidemiology Female Genetic Diseases, Inborn/diagnosis,epidemiology Genetic Predisposition to Disease/epidemiology Heterozygote Humans Incidence Male Middle Aged Multivariate Analysis Pancreatitis/epidemiology,genetics,surgery Pedigree Point Mutation Probability Prognosis Registries Reproducibility of Results Risk Assessment Severity of Illness Index Sex Distribution Survival Rate Trypsin Trypsinogen/genetics
Chemicals
Trypsinogen PRSS1 protein, human Trypsin
Authors & Affiliations
19 authors, click to expand affiliations / ORCID
Howes Nathan
Department of Surgery, University of Liverpool, United Kingdom.
Lerch Markus M
Greenhalf William
Stocken Deborah D
Ellis Ian
Simon Peter
Truninger Kaspar
Ammann Rudi
Cavallini Giorgio
Charnley Richard M
Uomo Generoso
Delhaye Miriam
Spicak Julius
Drumm Brendan
Jansen Jan
Mountford Roger
Whitcomb David C
Neoptolemos John P
European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC)
Article Info
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Abbr.
Clin Gastroenterol Hepatol
ISSN
1542-3565
Published
2004-03-00
Pages
252-61
Language
English
Region
United States
NLM ID
101160775
Subset
IM
Grants
NIDDK NIH HHS · DK54709 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com